文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

日本老年射血分数保留的心力衰竭前期女性血清总睾酮浓度的临床意义

Clinical Significance of Serum Total Testosterone Concentration in Japanese Elderly Women With Pre-Heart Failure With Preserved Ejection Fraction.

作者信息

Hitsumoto Takashi

机构信息

Hitsumoto Medical Clinic, Shimonoseki City, Yamaguchi 750-0025, Japan. Email:

出版信息

Cardiol Res. 2025 Jun 9;16(4):346-352. doi: 10.14740/cr2084. eCollection 2025 Aug.


DOI:10.14740/cr2084
PMID:40809732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12339276/
Abstract

BACKGROUND: Currently, limited information is available regarding testosterone in women with heart failure with preserved ejection fraction (HFpEF). This cross-sectional study aimed to elucidate the clinical significance of serum total testosterone concentration (T-T) in Japanese elderly women with pre-HFpEF, a condition that develops before the onset of HF. METHODS: A total of 232 elderly women outpatients with pre-HFpEF (mean age ± standard deviation, 75 ± 7 years) were enrolled. Relationships between T-T and other clinical parameters were investigated. The definition of pre-HFpEF in this study was that patients with left ventricular ejection fraction of 50% or more and E/e' ratio as a marker of left ventricular function greater than 9 on echocardiography had no HF symptoms and no history of HF hospitalization. RESULTS: There was a significantly negative correlation between T-T and the E/e' ratio (r = -0.24, P < 0.001), and low T-T was significantly related to coronary artery disease. A significant correlation was observed between T-T and biomarkers such as blood brain natriuretic peptide concentration (r = -0.31, P < 0.001), serum high-sensitivity cardiac troponin T concentration (r = -0.33, P < 0.001), and the derivatives-reactive oxygen metabolites test, an oxidative stress marker (r = -0.46, P < 0.001). Furthermore, multiple regression analysis identified that the factors described above were selected as independent variables for T-T as a dependent variable. CONCLUSIONS: This cross-sectional study indicated that low T-T levels reflect unfavorable pathophysiological conditions in Japanese elderly women with pre-HFpEF. To clarify the relevance of T-T as a predictive indicator for the onset of cardiovascular diseases, including HF incidence in elderly women with pre-HFpEF, future prospective studies, including interventional treatments, should be conducted.

摘要

背景:目前,关于射血分数保留的心力衰竭(HFpEF)女性患者的睾酮水平,相关信息有限。这项横断面研究旨在阐明血清总睾酮浓度(T-T)在日本老年女性射血分数保留的心力衰竭前期(HFpEF)患者中的临床意义,HFpEF是一种在心力衰竭发作前出现的病症。 方法:共纳入232例射血分数保留的心力衰竭前期老年女性门诊患者(平均年龄±标准差,75±7岁)。研究了T-T与其他临床参数之间的关系。本研究中射血分数保留的心力衰竭前期的定义为:超声心动图显示左心室射血分数为50%或更高且作为左心室功能标志物的E/e'比值大于9的患者,无心力衰竭症状且无心力衰竭住院史。 结果:T-T与E/e'比值之间存在显著负相关(r = -0.24,P < 0.001),低T-T与冠状动脉疾病显著相关。观察到T-T与生物标志物如血脑钠肽浓度(r = -0.31,P < 0.001)、血清高敏心肌肌钙蛋白T浓度(r = -0.33, P < 0.001)以及氧化应激标志物衍生的活性氧代谢产物检测(r = -0.46, P < 0.001)之间存在显著相关性。此外,多元回归分析确定上述因素被选为以T-T为因变量的自变量。 结论:这项横断面研究表明,低T-T水平反映了日本老年射血分数保留的心力衰竭前期女性患者的不良病理生理状况。为了阐明T-T作为包括射血分数保留的心力衰竭前期老年女性心力衰竭发病率在内的心血管疾病发病预测指标的相关性,应开展包括介入治疗在内的未来前瞻性研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a6f/12339276/b1b8ce765c03/cr-16-04-346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a6f/12339276/b1b8ce765c03/cr-16-04-346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a6f/12339276/b1b8ce765c03/cr-16-04-346-g001.jpg

相似文献

[1]
Clinical Significance of Serum Total Testosterone Concentration in Japanese Elderly Women With Pre-Heart Failure With Preserved Ejection Fraction.

Cardiol Res. 2025-6-9

[2]
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.

Cardiovasc Diabetol. 2025-3-22

[3]
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Cochrane Database Syst Rev. 2018-6-28

[4]
Prescription of Controlled Substances: Benefits and Risks

2025-1

[5]
Myocardial contrast echocardiography evaluation of coronary microvascular dysfunction to Predict MACEs in patients with heart failure with preserved ejection fraction follow-up.

BMC Cardiovasc Disord. 2024-9-18

[6]
Assessment of the Physical and Emotional Health-Related Quality of Life Among Congestive Heart Failure Patients with Preserved and Reduced Ejection Fraction at a Quaternary Care Teaching Hospital in Coastal Karnataka in India.

Healthcare (Basel). 2025-7-31

[7]
Estimated Pulse Wave Velocity-to-Global Longitudinal Strain Ratio: A Tool for Differentiating Heart Failure Subtypes?

Cardiology. 2025-5-23

[8]
Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial.

JAMA Cardiol. 2025-2-1

[9]
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].

Epidemiol Prev. 2013

[10]
Use of Spironolactone for the Treatment of Heart Failure With Preserved Ejection Fraction: Efficacy and Clinical Implications in Light of Recent Evidence.

Cureus. 2025-6-13

本文引用的文献

[1]
Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction.

BMC Endocr Disord. 2022-12-19

[2]
Validation of the MEDIA echo score for the prognosis of heart failure with preserved ejection fraction.

Heart Fail Rev. 2023-3

[3]
Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations.

ESC Heart Fail. 2022-12

[4]
Association of arterial stiffness and heart failure with preserved ejection fraction in the elderly population - results from the CARLA study.

J Hum Hypertens. 2023-6

[5]
EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction.

Glob Cardiol Sci Pract. 2021-10-30

[6]
Evaluation of the diagnostic accuracy of current biomarkers in heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Arch Cardiovasc Dis. 2021-12

[7]
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.

Nat Med. 2021-11

[8]
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

N Engl J Med. 2021-10-14

[9]
Biomarker profiling for risk of future heart failure (HFpEF) development.

J Transl Med. 2021-2-9

[10]
Epidemiology and pathogenesis of heart failure with preserved ejection fraction.

Rev Cardiovasc Med. 2020-12-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索